Neratinib: Phase I/II data

In a dose-escalation Phase I/II trial in 45 patients receiving neratinib plus Herceptin trastuzumab, there were no dose limiting toxicities. Grade 3/4 adverse events were diarrhea (13%), nausea (4%) ...